



ASX Announcement

Avexa secures meeting with US Food and Drug Administration on apricitabine

Melbourne, Australia, Wednesday 24 November, 2010: Australian biotechnology company Avexa Limited [ASX:AVX] today announced that it has secured a meeting with the US Food and Drug Administration to discuss the company's anti-HIV drug apricitabine (ATC).

The meeting is scheduled to take place in the first quarter of calendar 2011.

Joe Baini, Chairman of Avexa, said: "This meeting with the FDA marks a very important opportunity for Avexa and ATC. We will be able to present the most recent data from our Phase II/III to the Agency and discuss possible paths forward for ATC."

End

About Avexa Limited: Avexa Limited is a Melbourne-based biotechnology company with a focus on discovery, development and commercialisation of small molecules for the treatment of infectious diseases. Avexa's key projects include apricitabine (ATC) for the treatment of drug-resistant HIV, an HIV integrase program and an antibiotic program for antibiotic-resistant bacterial infections.

For more information:

Mr Joe Baini
Avexa Chairman
Ph: +61 3 9208 4300

Dr Jonathan Coates
Avexa Interim CEO
Ph: +61 3 9208 4300

Richard Allen
Oxygen Financial Public Relations
Ph: + 61 3 9915 6341

www.avexa.com.au